10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Sanofi Pasteur revealed today it plans to leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a novel coronavirus (COVID-19) vaccine. 18 February 2020
Government-funded non-profit CARB-X has taken a punt on another company that could help to tackle the emerging antimicrobial resistance crisis. 18 February 2020
Independent drugmaker Servier and fellow France-based biotech Oncodesign (Euronext: ALONC) late Monday announced reaching an important milestone in their strategic partnership on potential drug candidates for Parkinson’s disease, news of which sent Oncodesign’s shares leaping 17% to 11.70 euros in early trading this morning. 18 February 2020
The first patients in England have been treated with Novartis’ Luxturna (voretigene neparvovec), after the company reached a reimbursement deal in the UK in late 2019. 18 February 2020
Ahmedabad-based Zydus Cadila, a part of Cadila Healthcare, has launched an accelerated research program to develop a vaccine for the novel coronavirus, COVID-19. 17 February 2020
As has been widely expected following a positive advisory panel recommendation last December, the European Commission (EC) has now granted approval for Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). 17 February 2020
Shares of UK-based ReNeuron Group rose as much as 4% in early trading, as the company announced the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase IIa clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke. 17 February 2020
The Chinese Communist Party has said that biotech companies located at the heart of the coronavirus outbreak can now return to work, reports GlobalData. 14 February 2020
Japanese drug major Chugai today said that polatuzumab vedotin in combination with bendamustine and rituximab (hereafter, BR therapy) had achieved the primary endpoint of complete response rate (CRR) by PET-CT at the timing of Primary Response Assessment (PRA) in the Japanese Phase II study (JO40762/P-DRIVE study). 14 February 2020
Continuing its progress in addressing different cancer types across different geographies, immuno-oncology blockbuster Tecentriq (atezolizumab) has secured Chinese approval in extensive-stage small cell lung cancer (ES-SCLC). 14 February 2020
As high drug prices continue to incite public outcry and US legislation, it is nonetheless possible that Regeneron Pharmaceuticals’ (Nasdaq: REGN) drug for a rare cholesterol condition could lock in as much as $500,000 annually. 14 February 2020
US clinical-stage synthetic biology company Codagenix has entered into a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. 13 February 2020
US pharma major Bristol-Myers Squibb today announced that the US Food and Drug Administration has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel). 13 February 2020
Tumor drug resistance specialist Deciphera Pharmaceuticals yesterday revealed that the US Food and Drug Administration has accepted for priority review its New Drug Application (NDA) seeking approval for ripretinib. 13 February 2020
Nordic biotech firm Swedish Orphan Biovitrum today announced its results for the fourth quarter and full-year 2019. Revenue growth for the full-year was 56% with sales of 14,248 million Swedish kronor ($1.48 billion). 13 February 2020
In early morning trading on Thursday, shares in Paris-based drugmaker Ipsen slumped nearly 6% following a results statement showing revenues of 2.57 billion euros ($2.8 billion) for full-year 2019, a little under the FT’s consensus estimate. 13 February 2020
Shares in US biotech CytoDon were 7% up after Wednesday morning's trading following news of a development and licensing deal for leronlimab in China. 13 February 2020
ElevateBio portfolio company AlloVir revealed today that the European Medicines Agency has granted PRIority MEdicines (PRIME) designation to Viralym-M (ALVR105). 12 February 2020